MLTX Stock Summary and Trading Ideas (Moonlake Immunotherapeutics - Class A | NASDAQ:MLTX)

MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.

Moonlake Immunotherapeutics - Class A trades on the NASDAQ stock market under the symbol MLTX.

As of August 14, 2026, MLTX stock price declined to $16.47 with 909,086 million shares trading.

MLTX has a beta of -0.36, meaning it tends to be less sensitive to market movements. MLTX has a correlation of 0.00 to the broad based SPY ETF.

MLTX has a market cap of $1.40 billion. This is considered a Small Cap stock.

In the last 3 years, MLTX traded as high as $64.98 and as low as $5.95.

The top ETF exchange traded funds that MLTX belongs to (by Net Assets): TCAF, VHT, ESML, NUSC, ONEQ.

MLTX has underperformed the market in the last year with a price return of -70.4% while the SPY ETF gained +21.6%. MLTX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -10.5% and -13.3%, respectively, while the SPY returned +4.8% and +4.7%, respectively.

MLTX support price is $15.85 and resistance is $17.15 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MLTX shares will trade within this expected range on the day.